Metagenomi Inc
NASDAQ:MGX
Relative Value
The Relative Value of one MGX stock under the Base Case scenario is 4.97 USD. Compared to the current market price of 6.8 USD, Metagenomi Inc is Overvalued by 27%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MGX Competitors Multiples
Metagenomi Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
M
|
Metagenomi Inc
NASDAQ:MGX
|
255.2m USD | 5.7 | -3.7 | 0.2 | 0.2 | |
US |
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 5.8 | 45.5 | 19.1 | 31.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.4 | 31.1 | 25.2 | 26.4 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.2 | 27.9 | 22.6 | 25.1 | ||
AU |
CSL Ltd
ASX:CSL
|
136.7B AUD | 6.5 | 37.1 | 22.3 | 27.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.5B USD | 3 | 172.5 | 6.9 | 9.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
49.4B USD | 9.6 | -8.3 | -9.1 | -8.1 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
34.3B USD | 3.5 | 29.4 | 14.9 | 18.6 | ||
KR |
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |